NCT03877458

Brief Summary

All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group. Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to \<3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 16, 2017

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 15, 2019

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 11, 2021

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

March 22, 2023

Status Verified

March 1, 2023

Enrollment Period

4.7 years

First QC Date

March 12, 2019

Last Update Submit

March 21, 2023

Conditions

Keywords

Infantile ColicBifidobacteria and LactobacilliIntestinal MicrobiomeProbiotics

Outcome Measures

Primary Outcomes (1)

  • Average crying and fussing times.

    Change in the duration of average crying and fussing times from baseline (day 0) to age 6 months, to \<3 hours per day.

    6 months.

Secondary Outcomes (1)

  • The number of participants.

    6 months.

Study Arms (3)

L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088

EXPERIMENTAL

Taking 1 mix probiotics capsule at bed time everyday for three months.

Other: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088

L. reuteri GL-104

EXPERIMENTAL

Taking 1 probiotic capsule at bed time everyday for three months.

Other: L. reuteri GL-104

Placebo group

PLACEBO COMPARATOR

Taking 1 Placebo capsule at bed time everyday for three months.

Other: Placebo

Interventions

Taking 1 mix probiotics capsule at bed time everyday for three months.

L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088

Taking 1 probiotic capsule at bed time everyday for three months.

L. reuteri GL-104
PlaceboOTHER

Taking 1 placebo capsule at bed time everyday for three months.

Placebo group

Eligibility Criteria

Age3 Weeks - 3 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement.
  • Age 3 weeks to 3 months at study commencement.
  • Infants are born in full term (greater than 37 weeks) and the birth weight more than 2500 grams.

You may not qualify if:

  • A major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician.
  • History of antibiotic treatment before or during the study.
  • History of probiotic supplementation.
  • History of any allergies to any of the ingredients in the probiotic mixture of L. acidophilus, B. longum and B. bifidum or placebo.
  • Concurrent participation in another clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University Hospital

Taichung, 40447, Taiwan

Location

MeSH Terms

Conditions

Colic

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Hung-chih Lin

    China Medical University Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending physician

Study Record Dates

First Submitted

March 12, 2019

First Posted

March 15, 2019

Study Start

February 16, 2017

Primary Completion

November 11, 2021

Study Completion

December 31, 2022

Last Updated

March 22, 2023

Record last verified: 2023-03

Locations